CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of Everett Crosland as Chief Commercial Officer. In this role, Everett will drive key commercialization activities at Cognito in conjunction with the leadership team.
Everett was most recently Chief Commercial Officer at AppliedVR, where he led national launch sales, marketing, and payer strategy on the first breakthrough designated virtual reality therapeutic. Prior to AppliedVR, he was VP of Market Access & Reimbursement with Pear Therapeutics, leading payer, reimbursement, and government strategy on the first breakthrough designated digital therapeutic. In past roles he has led the launch readiness and market access and reimbursement commercialization of novel infused and oral drugs, drug-device combinations, and digital therapeutics.
“As Cognito prepares to launch our pivotal study for disease modification in Alzheimer’s disease with our lead breakthrough digital medical device later this year, we are excited to have Everett join us to further strengthen our leadership team,” said Brent Vaughan, Chief Executive Officer, Cognito Therapeutics. “His depth of knowledge in reimbursement, market access and bringing novel treatments to market will be invaluable, as we advance development of our pipeline of disease-modifying digital medical devices targeting debilitating neurodegenerative diseases.”
“I look forward to working with Brent and the rest of the executive leadership team to capitalize on this transformative near-term opportunity, in addition to helping advance Cognito’s deep pipeline of next-generation digital medical devices targeting neurodegenerative disorders,” said Everett Crosland, Chief Commercial Officer, Cognito Therapeutics. “Alzheimer’s is a clinically and financially devastating disease, as the sixth leading cause of death, and consumes nearly 20% of Medicare’s total annual budget. Based on Cognito’s internal research, an overwhelming number of payers say they’ll cover it, with 9/10 HCPs eager to prescribe this new therapy, which is promising as new therapies are desperately needed for patients with this debilitating disorder.”
Everett received a B.S. from Georgetown University. He also received a Masters degree in Biotechnology from Johns Hopkins University and obtained his J.D. from the University of Maryland Francis King Carey School of Law.
About Cognito Therapeutics
Cognito Therapeutics is a clinical-stage company developing a pipeline of digital therapeutics that have shown disease-modifying effects to treat neurodegenerative disorders including Alzheimer’s disease. The company’s licensed proprietary neuromodulation platform technology, developed by scientific founders at MIT, Professors Li-Huei Tsai and Ed Boyden is a non-invasive, neurostimulation therapy utilizing visual and auditory stimulation to treat neurodegenerative diseases. The company is based in Boston and San Francisco. For more information, please visit www.cognitotx.com. Follow us on Twitter at @cognitotx.
